Ingalls & Snyder LLC Purchases 200 Shares of Amgen Inc. (NASDAQ:AMGN)

Ingalls & Snyder LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,660 shares of the medical research company’s stock after acquiring an additional 200 shares during the period. Ingalls & Snyder LLC’s holdings in Amgen were worth $4,082,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Castle Wealth Management LLC grew its stake in shares of Amgen by 5.1% in the 4th quarter. Castle Wealth Management LLC now owns 3,681 shares of the medical research company’s stock valued at $959,000 after purchasing an additional 177 shares during the period. Hidden Cove Wealth Management LLC bought a new stake in shares of Amgen in the 4th quarter valued at approximately $293,000. Naples Global Advisors LLC grew its stake in shares of Amgen by 2.4% in the 4th quarter. Naples Global Advisors LLC now owns 35,006 shares of the medical research company’s stock valued at $9,124,000 after purchasing an additional 836 shares during the period. Van ECK Associates Corp grew its stake in shares of Amgen by 263.8% in the 4th quarter. Van ECK Associates Corp now owns 1,038,593 shares of the medical research company’s stock valued at $270,699,000 after purchasing an additional 753,147 shares during the period. Finally, Values First Advisors Inc. grew its stake in shares of Amgen by 90.7% in the 4th quarter. Values First Advisors Inc. now owns 593 shares of the medical research company’s stock valued at $154,000 after purchasing an additional 282 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several analyst reports. Bank of America upped their price objective on Amgen from $256.00 to $275.00 and gave the company an “underperform” rating in a research note on Thursday, February 6th. Redburn Partners reduced their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Piper Sandler boosted their target price on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a report on Monday. Deutsche Bank Aktiengesellschaft reduced their target price on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Finally, Piper Sandler Companies reissued an “overweight” rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus price target of $314.09.

Amgen Stock Performance

AMGN stock opened at $295.06 on Thursday. The business’s fifty day moving average is $272.96 and its 200-day moving average is $302.23. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a market cap of $158.60 billion, a P/E ratio of 39.08, a price-to-earnings-growth ratio of 3.01 and a beta of 0.56. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts forecast that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.23%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 119.21%.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their position. The disclosure for this sale can be found here. 0.69% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.